

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/505</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/53923</b> <b>(43) International Publication Date:</b> 28 October 1999 (28.10.99)
<b>(21) International Application Number:</b> PCT/AU99/00294 <b>(22) International Filing Date:</b> 20 April 1999 (20.04.99)  <b>(30) Priority Data:</b> PP 3107 22 April 1998 (22.04.98) AU  <b>(71) Applicant (for all designated States except US):</b> SOLTEC RE-SEARCH PTY. LTD. [AU/AU]; 8 Macro Court, Rowville, VIC 3178 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WAI-CHIU SO, Tony [AU/AU]; 7 Marsden Crescent, Doncaster East, VIC 3109 (AU). DEO, Peter, Paul [AU/AU]; 3/119 Atkinson Street, Oakleigh, VIC 3166 (AU). TAIT, Russell, John [AU/AU]; 33 Campbell Road, Deepdene, VIC 3103 (AU).  <b>(74) Agents:</b> NOONAN, Greg et al.; Freehills Patent Attorneys, Level 47, 101 Collins Street, Melbourne, VIC 3000 (AU).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION  <b>(57) Abstract</b>  A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5 % by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10 % by weight.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## PHARMACEUTICAL COMPOSITION

### Background of the invention

The present invention relates to a vehicle system for a pharmaceutical composition comprising a piperidinopyrimidine derivative. More particularly  
5 minoxidil and to a pharmaceutical composition incorporating the vehicle system. Minoxidil is a pharmaceutically active ingredient having several indications including use as a hair growth stimulant.

Minoxidil has poor solubility in water and ethanol and pharmaceutical preparations currently marketed only contain a small percentage of minoxidil.  
10 That is, below 5%.

Numerous formulations comprising minoxidil have been published in the prior art including United States patents 4,139,619, 4,820,512, 5,104,646, 5,225,189, 4,938,953, 4,596,812, 5,006,332, 5,156,836 and 5,643,942. Many of the formulations require (or would require where the amount of minoxidil is greater  
15 than 5%) a very high percentage (often in the range of 30 to 50%) of propylene glycol or a similar glycol product in order to improve the solubility of minoxidil. Due to the viscosity and tack of propylene glycol, large amounts of propylene glycol or similar agents in a composition are not pharmaceutically or cosmetically elegant and may be unacceptable to the consumer. In addition, high concentrations of  
20 propylene glycol may cause local irritation and hypersensitivity upon application to the scalp.

It would accordingly be a significant advance in the art if a composition could be provided which would permit the inclusion of an increased percentage of the active ingredient, but without the disadvantages associated with a high  
25 propylene glycol concentration.

Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties and deficiencies related to the prior art. These and other objects and features of the present invention will be clear from

the following disclosure.

### Summary of the invention

Accordingly, the present invention in a first aspect provides a pharmaceutical composition for topical administration, including, as the  
5 pharmaceutically active component,

at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

10 a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

15 Applicants have surprisingly discovered that by adjusting the acid concentration of the composition the solubility of the piperidinopyrimidine derivatives may be significantly increased without the necessity of utilising large amounts of propylene glycol or optionally by excluding propylene glycol altogether. Accordingly the total amount of active in the composition may be significantly  
20 increased. In a preferred form, the pharmaceutically active component is present in amounts of approximately 5 to 25% by weight, preferably approximately 5 to 15% by weight, more preferably approximately 7.5 to 12% by weight.

Preferably the piperidinopyrimidine derivative is minoxidil. Preferably the minoxidil is present in the form of a salt. The salt may include acetate, citrate,  
25 succinate, benzoate, hydrochloride, sulphate, phosphate or lactate. Preferably an acetate or lactate salt of minoxidil is used. The acetate or lactate salts may exhibit enhanced solubility and improve the ability to incorporate increased amounts of the active component in the composition.

In a preferred form the acid is added in an amount sufficient to provide an

apparent pH to the composition of approximately 7.0 or less. The apparent pH of the composition is preferably between approximately 5.0 to 7.0, more preferably between 6.0 to 6.5. Any suitable acid may be used to adjust the pH, including mineral acids, such as hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid, or organic acids such as citric acid, acetic acid, succinic acid, or maleic acid, or mixtures thereof. Acetic acid or lactic acid is preferred.

In a preferred form the acid is present at a level that provides at least 0.01 Normal acid. Alternatively, the acid is present in an amount equal to, or greater than, the amount of the piperidinopyrimidine derivative in Normal amounts.

10 Preferably the lower alcohol is ethanol. The ratio of water to ethanol is preferably from approximately 9:1 to 1:9, more preferably approximately 1:1 to 1:3, by volume.

Preferably, the co-solvent includes benzyl alcohol. The benzyl alcohol may be present in amounts of approximately 2.5 to 95% by weight, preferably approximately 5 to 40% by weight, based on the total weight of the pharmaceutical composition.

Alternatively, or in addition the co-solvent may include a polyhydric alcohol, for example a polyol selected from the group consisting of 1,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol. When propylene glycol is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight, or less.

In compositions comprising 5% of minoxidil or greater, it is preferred to include benzyl alcohol in the composition. The benzyl alcohol may be present in amounts of up to 85% by weight, based on the total weight of the pharmaceutical composition.

In a preferred form the co-solvent system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by

weight, based on the total weight of the co-solvent system.

In a preferred form the water is present in an amount no greater than 60% by weight.

In a preferred aspect, the pharmaceutical composition includes  
5 approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;  
approximately 88 to 95% by weight of a solvent composition including  
approximately 10 to 70% by weight of ethanol,  
approximately 2.5 to 85% by weight of benzyl alcohol;  
10 and less than 10% by weight, propylene glycol.

The final presentation of the composition may be any suitable topical pharmaceutical preparation and may include solutions, lotions, ointments, mousses, foams, sprays, aerosols, shampoos and/or conditioners, gels, creams, pastes, and other preparations known in the art. The composition may also  
15 include other ingredients such as preservatives, buffers, stabilisers, propellants and the like.

Preferably the pharmaceutical composition is a mousse composition. The mousse composition may include a suitable propellant, for example hydrocarbons or chlorofluorocarbons. Alternatively the pharmaceutical composition may be a  
20 gel composition. The gel composition may include a suitable gelling agent, e.g. a cellulose derivative. A hydroxy propyl cellulose, for example that sold under the trade designation Klucel M, has been found to be suitable.

Where an aerosol formulation is used, the aerosol formulation may be a homogeneous, aqueous-alcoholic emulsion system. The aerosol formulation  
25 upon actuation produces a stabilized, homogeneous, expandable foam which breaks easily with shear. A composition of this type is sometimes referred to as a "mousse".

In a further preferred aspect, the pharmaceutical composition according to

the present invention may further include an effective amount of a skin penetrating agent.

Suitable skin penetrating agents include alcohols such as dodecanol and oleyl alcohol; amines, such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine; carboxylic acids, such as oleic acid, linoleic acid and linolenic acid; esters, such as dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate; and others, such as Azone, N methyl pyrrolidone, bile salts and urea.

All of the compositions herein may be actuated using propellants known per se in the pharmaceutical or cosmetic fields. Such propellants include hydrocarbons such as propane, isobutane or dimethyl ether and chlorofluorocarbons such as P-12, P114, and a 40:60 mixture thereof.

In the pharmaceutical composition according to the present invention, in addition to the above essential components, general purpose components ordinarily used in hair treatment compositions can be formulated, within a range which does not impair the effect of the present invention, including vitamins such as vitamin B.sub.6, vitamin E and derivatives thereof, and biotin; hair generating agents or hair generating aids such as panthothenic acid and derivatives thereof, glycyrrhetic acid and derivatives thereof, nicotinic acid esters such as benzyl nicotinate, cyclosporins, carpronium chloride, cepharanthine, oxendolone, diazoxide, minoxidil, and ethynylesteradiol; antibacterial agents such as hinokitiol, hexachlorophen, phenol, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, and bithionol; refrigerants such as menthol; drugs such as salicylic acid, zinc and derivatives, thereof, and lactic acid and alkyl esters thereof; amino acids such as arginine; oil components such as olive oil, squalane, fluid paraffin, isopropyl myristate, higher fatty acids, and higher alcohols; perfumes; antioxidants; UV-ray absorbers; dyes; humectants; thickeners; perfumes; colour additives and the like.

In a still further aspect of the present invention, there is provided a method for the treatment of hair loss and related indications in humans, which method

includes

providing

a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,

5 at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

10 a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and

15 applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.

The hair loss may be related to any of the forms of alopecia including male pattern alopecia. Related indications may include weakening of hair strength, loss of hair colour and the like.

20 Preferably the pharmaceutically active component includes a minoxidil or a minoxidil salt, more preferably a minoxidil acetate, succinate or citrate salt.

More preferably the pharmaceutical composition includes approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;

25 approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.

The present invention will now be more fully described with reference to the  
30 accompanying figures and examples. It should be understood, however, that the



description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.

In each of the following examples it was necessary to add an appropriate amount of acid to ensure equivalent acid normality. The standard technique for  
5 such an adjustment is to measure the apparent pH of the solution.

In the examples, the apparent pH of each formulation was measured once prepared. The measured taken as the apparent pH due to the high proportion of organic modifiers in the formulations. Typically, 0.5% (w/w) glacial acetic acid (0.1M) would be used in the formulation, which would equate to a pH of 1.0 in an  
10 aqueous system when no other components are contributing to the pH of the solution.

### EXAMPLE 1

#### Topical Minoxidil lotion 5% with no propylene glycol

Minoxidil	5.00%
Ethanol	60.3%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	0.6
Purified Water	to total 100%

15 The apparent pH of the final formulated solution was measured at 6.24.

**EXAMPLE 2****Topical Minoxidil mousse 5% for hair treatment**

Minoxidil	5.00%
Cetyl Alcohol	2.20%
Stearyl Alcohol	1.00%
Ethanol	51.8
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Propylene Glycol	5.00%
Propellant P75	4.30%
Acetic Acid	qs. pH 6.0
Purified water	to total 100%

**EXAMPLE 3**

5

**Topical Minoxidil lotion 8% for hair treatment**

Minoxidil	8.00%
Ethanol	50.50%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Nitric Acid	qs. pH 6.0
Propylene Glycol	7.30%
Benzyl Alcohol	5.00%
Purified Water	to total 100%

**EXAMPLE 4****Topical 8% (w/w) Minoxidil solution**

Minoxidil	8.0%
Ethanol	50.5%
Crilet 3	0.4%
Teric 12A4	1.0%
Glacial Acetic Acid	0.3%
Propylene Glycol	7.5%
Benzyl Alcohol	5.0%
Purified Water	to total 100%

The apparent pH of the final formulated solution was measured at 6.24.

5

**EXAMPLE 5****Topical Minoxidil lotion 10% for hair treatment**

Minoxidil	10.00%
Ethanol	48.0%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Propylene Glycol	10.0%
Benzyl Alcohol	5.00%
Purified Water	to total 100%

**EXAMPLE 6****Topical Minoxidil lotion 10% for hair treatment**

Minoxidil	10.00%
Ethanol	47.50%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Benzyl Alcohol	15.00%
Purified Water	to total 100%

**EXAMPLE 7**

5

**Topical 10% (w/w) Minoxidil solution**

	Formulation 3a	Formulation 3b
Minoxidil	10.00%	10.00%
Ethanol	46.80%	44.20%
Crillet 3	0.4%	0.4%
Teric 12A4	1.0%	1.0%
Glacial Acetic Acid	1.0%	0.3%
Propylene Glycol	10.0%	nil
Benzyl Alcohol	5.00%	2.00%
Purified Water	to total 100%	to total 100%

The apparent pH of the final formulated solutions was measured at 6.0 and 6.5 for formulations 3a and 3b, respectively.

**EXAMPLE 8****Topical Minoxidil lotion 11% for hair treatment**

Minoxidil	11.00%
Ethanol	44.20%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Benzyl Alcohol	20.00%
Purified Water	to total 100%

**EXAMPLE 9**

5

**Topical Minoxidil lotion 12% for hair treatment**

Minoxidil	12.00%
Ethanol	42.7%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Benzyl Alcohol	20.00%
Purified Water	to total 100%

**EXAMPLE 10****Topical Minoxidil lotion 12% for hair treatment**

Minoxidil	12.00%
Ethanol	42.7%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Benzyl Alcohol	10.00%
Propylene Glycol	10.00%
Purified Water	to total 100%

**EXAMPLE 11**

5

**Topical Minoxidil lotion 12% for hair treatment**

Minoxidil	12.00%
Ethanol	42.7%
Polysorbate 60	0.4%
Polyoxyethylene lauryl alcohol	1.00%
Acetic Acid	qs. pH 6.0
Benzyl Alcohol	15.00%
Propylene Glycol	5.00%
Purified Water	to total 100%

There appear to be no obvious gross stability issues associated with any of the formulations. The levels of minoxidil were assayed in formulations 1 and 3a after they had been stored for one and three months at 4°C and 50°C. No  
10 measurable loss in potency was observed.

An aqueous gel was prepared by adding 0.75% (w/w) Klucel M (hydroxypropyl cellulose) to Example 4. The viscosity of the gel was measured at

2400 cPoise at 20°C.

## EXAMPLE 12

Investigations were carried out to determine which of the components present in Example 7 (10% (w/w) minoxidil solution) were contributing to the solubilisation of minoxidil. The investigation was split into three sections:

- Effect of Co-solvent
- Effect of pH
- Effect of Salt

The solubility determination involved preparation of saturated solutions of minoxidil in the media of interest. These solutions were then filtered (0.45 µm) and analysed against a standard curve by means of direct UV spectroscopy.

### Aqueous unbuffered solubility of Minoxidil

The aqueous solubility of minoxidil was found to be 2.2 mg/mL.

### Effect of Co-solvent

The solubility of minoxidil was determined in each of the co-solvents, benzyl alcohol, glycerol, propylene glycol and ethanol. Additionally, the solubility of minoxidil was determined in 10% (w/w) solutions of each of the co-solvents, ethanol, propylene glycol and glycerol in water. A 4% (w/w) solution of benzyl alcohol was used since this was found to be the limit of the solubility of benzyl alcohol in water. The following table summarises the results of these studies.

Sample	Minoxidil Solubility (mg/mL)
Benzyl alcohol	125.1
Glycerol	47.3
Propylene Glycol	86.9
Ethanol	18.8
10% (w/w) Ethanol/Water	3.4
10% (w/w) Propylene Glycol/Water	3.0
4% (w/w) Benzyl Alcohol/Water	4.5
10% (w/w) Glycerol/Water	2.7

Analysis indicated that of the systems studied only the use of pure benzyl alcohol would result in the desired 10% (w/w) minoxidil solution.

#### Effect of apparent pH

- 5        Attempts were made to prepare saturated solutions of minoxidil in acetate buffers at apparent pH's 2.5, 3.5, 4.6, 5.0 and 6.0. Saturated solutions were achieved with those pHs above the pKa of minoxidil (4.61), the results of which are summarised in the following table.

pH	Minoxidil Solubility (mg/mL)
6.0	2.5
5.0	4.1
4.6	11.3

- 10        It was not possible to determine the solubility limits of minoxidil at pH's below it's pKa, as minoxidil was found to be extremely soluble in acidic media and the buffer used had insufficient capacity to avoid the drift in pH observed with additions of minoxidil to the solution. The maximum minoxidil concentration studied was 22 mg/mL and was found to be completely soluble in pH 2.5 and 3.5
- 15        solutions at this concentration. The following table outlines the maximum solubility that would be expected in an acidic aqueous media knowing the solubility of the



base form of minoxidil is 2.2 mg/mL and assuming infinite solubility of the acid form of minoxidil.

pH	Minoxidil Solubility (mg/mL)
3.6	22.0
3.0	87.6
2.6	220.0
2.0	876.0

### Effect of Salt

- 5 Minoxidil base was used for these studies with the appropriate salt (acetate or HCl) formed *in situ*. As discussed above the use of low pH acetate buffers significantly increased the solubility of minoxidil.

The major factors affecting the solubilisation of minoxidil in an aqueous environment were found to be:

- 10 The type and proportion of co-solvents present in the formulation  
The pH of the final formulated solution  
The amount of minoxidil used

- 15 The acid form of minoxidil has been shown to be much more soluble in an aqueous environment. The use of co-solvents has been shown to enhance the solubility of the minoxidil free base. The co-solvents may also enhance the solubility of the acid form. The use of an appropriate salt enhances the solubility of the acid form of minoxidil. Therefore, a combination of these three factors may be used to optimise the solubility of minoxidil in a topical solution based formulation.

- 20 All the above examples were stored at room temperature and no crystallisation or precipitation was observed for at least 10 days.

Please note all percentages are based upon the total weight of the

composition unless otherwise specified.

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these  
5 different combinations constitute various alternative aspects of the invention.

It will also be understood that the term "comprises" (or its grammatical variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements or features.

**CLAIMS**

1. A pharmaceutical composition for topical administration, including, as the pharmaceutically active component,  
at least 5% by weight, based on the total weight of the composition of a  
5 piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;  
an acid in an amount to substantially completely solubilise the  
piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof  
a solvent composition including a solvent selected from water and/or a  
lower alcohol and a co-solvent selected from one or more of the group consisting  
10 of aromatic and polyhydric alcohols; wherein when the co-solvent includes  
propylene glycol, it is present in an amount of less than approximately 10% by  
weight.
2. A pharmaceutical composition according to Claim 1, wherein the acid is  
added in an amount sufficient to provide an apparent pH to the composition of  
15 approximately 7.0 or less.
3. A pharmaceutical composition according to Claim 1, wherein the  
pharmaceutically active component is present in an amount of from approximately  
5 to 25% by weight, based on the total weight of the pharmaceutical composition.
4. A pharmaceutical composition according to Claim 3, wherein the  
20 pharmaceutically active component is present in an amount of approximately 7.5  
to 12% by weight, based on the total weight of the pharmaceutical composition.
5. A pharmaceutical composition according to Claim 1, wherein the  
pharmaceutically active component is minoxidil or a salt thereof.
6. A pharmaceutical composition according to Claim 2, wherein the acid  
25 provides to the composition an apparent pH in the range of approximately 5.0 to  
7.0.
7. A pharmaceutical composition according to Claim 2, wherein the acid is a

mineral or organic acid.

8. A pharmaceutical composition according to Claim 7, wherein the acid includes acetic or lactic acid.
9. A pharmaceutical composition according to Claim 1, wherein the solvent  
5 composition includes water and ethanol in a range of approximately 1:1 to 1:3 by volume.
10. A pharmaceutical composition according to Claim 1, wherein the co-solvent includes benzyl alcohol.
- 10 11. A pharmaceutical composition according to Claim 1, wherein the solvent composition system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent system.
- 15 12. A pharmaceutical composition according to Claim 1, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the co-solvent system.
13. A pharmaceutical composition according to Claim 1, wherein the co-solvent includes an alkylene glycol.
- 20 14. A pharmaceutical composition according to Claim 13, wherein the alkylene glycol is selected from one or more of the group consisting of glycerol, 1,3-butylene or propylene glycol.
15. A pharmaceutical composition according to Claim 1, wherein the acid is present at a level that provides at least 0.01 Normal acid.
- 25 16. A pharmaceutical composition according to Claim 1, wherein the acid is present in an amount equal to or greater than the amount of the piperidinopyrimidine derivative in Normal amounts.

17. A pharmaceutical composition according to Claim 1, wherein the solvent system includes water and ethanol in a range of approximately 9:1 to 1:9 by volume.
18. A pharmaceutical composition according to Claim 5, wherein the pharmaceutically active component is a minoxidil salt.
19. A pharmaceutical composition according to Claim 18, wherein the minoxidil salt is a minoxidil acetate or lactate salt.
20. A pharmaceutical composition according to Claim 1, including approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;  
approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.
21. A method for the treatment of hair loss and related indications in humans, which method includes providing a pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and applying topically to the human scalp a therapeutically or prophylactically

effective amount of the pharmaceutical composition.

22. A method according to Claim 21, wherein the pharmaceutically active component includes minoxidil or a minoxidil salt.

23. A method according to Claim 22, wherein the minoxidil salt is a minoxidil acetate or lactate salt.

24. A method according to Claim 21, wherein the pharmaceutical composition includes

approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil salt;

10 approximately 88 to 95% by weight of a solvent composition including  
approximately 10 to 70% by weight of ethanol,  
approximately 2.5 to 85% by weight of benzyl alcohol;  
and less than 10% by weight, propylene glycol.

25. A pharmaceutical composition according to Claim 1, substantially as herein  
15 before described with reference to any one of the examples.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU 99/00294

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																						
Int Cl <sup>6</sup> : A61K 031/505																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
<b>B. FIELDS SEARCHED</b>																						
Minimum documentation searched (classification system followed by classification symbols) A61K 031/505																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC AS ABOVE.																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT: minoxidil, acid CAPLUS: minoxidil, acid																						
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	US 5183817A ( BAZZANO ) 2 February 1993 Column 24 lines 11-51.	1-25																				
X	US 4866067 ( DI SCHIENA ) 12 September 1989 Column 3.	1-25																				
X	WO 8302558A ( BAZZANO ) 4 August 1983 Page 8.	1-25																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 13 May 1999		Date of mailing of the international search report 19 MAY 1999																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  G.R.PETERS Telephone No.: (02) 6283 2184																				

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00294

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 07048230A ( JAPATIC ENGLISH LANGUAGE ABSTRACT ) ( HORIUCHI HIDEO et al ) 21 February 1995.	1-25



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/AU 99/00294**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
<u>US 5183817</u>	EP 71598, WO 8202833
<u>US 4866067</u>	None.
<u>WO 8302558</u>	US 5514672, US 5183817, EP 71598
<u>JP 07048230</u>	None
END OF ANNEX	

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**